No, Viibryd is NOT approved for use in a 15-year-old
Viibryd (vilazodone) is explicitly not approved for use in children or adolescents, including 15-year-olds. The FDA drug label clearly states: "VIIBRYD is not for use in children" and "It is not known if VIIBRYD is safe and effective for use in children for the treatment of MDD" 1.
Key Points from FDA Labeling
The official prescribing information is unequivocal:
- Approved population: Adults only with Major Depressive Disorder
- Pediatric use: Not approved for any age under 18 years
- Black box warning: Increased risk of suicidal thoughts or actions in children, adolescents, and young adults under 24 years of age 1
Supporting Clinical Evidence
The lack of approval is supported by failed efficacy trials. A Phase 3 randomized controlled trial in adolescents aged 12-17 years (n=529) found that vilazodone failed to demonstrate statistically significant efficacy compared to placebo for treating MDD in this age group 2. This negative trial was a key factor in the FDA's decision not to extend approval to pediatric populations.
Critical Safety Concerns in Pediatric Populations
Vilazodone poses particularly serious risks to children and adolescents:
- Seizure risk: Multiple case reports document seizures, including refractory status epilepticus, in children after vilazodone ingestion 3
- Serotonin syndrome: Children develop this life-threatening condition at much lower doses than adults 4, 5
- Higher toxicity: Pediatric ingestions result in 9-fold higher odds of hospital admission and 20-fold higher odds of major/moderate outcomes compared to other SSRIs 4
- Low threshold for toxicity: Children have experienced major clinical toxicity from ingesting as little as 10 mg (the minimum adult daily dose) 5
Clinical Bottom Line
Do not prescribe Viibryd to a 15-year-old. If depression treatment is needed, use FDA-approved alternatives for adolescents (fluoxetine is the only SSRI with FDA approval for pediatric MDD) 6. If a 15-year-old has accidentally ingested vilazodone, this requires immediate medical evaluation in a monitored setting due to high risk of seizures and serotonin syndrome.